DOCSLIB.ORG

Chlamydia Trachomatis WHO Library Cataloguing-In-Publication Data WHO Guidelines for the Treatment of Chlamydia Trachomatis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chlamydia Trachomatis WHO Library Cataloguing-In-Publication Data WHO Guidelines for the Treatment of Chlamydia Trachomatis WHO GUIDELINES FOR THE Treatment of Chlamydia trachomatis WHO Library Cataloguing-in-Publication Data WHO guidelines for the treatment of Chlamydia trachomatis. &RQWHQWV:HEDQQH['(YLGHQFHSURnjOHVDQGHYLGHQFHWRGHFLVLRQ framework -- Web annex E: Systematic reviews -- Web annex F: Summary RIFRQǍLFWVRILQWHUHVW 1.Chlamydia trachomatis. 2.Chlamydia Infections - drug therapy. 3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization. ,6%1 1/0FODVVLnjFDWLRQ:& © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are DYDLODEOHRQWKH:+2ZHEVLWH KWWSZZZZKRLQW RUFDQEHSXUFKDVHG IURP:+23UHVV:RUOG+HDOWK2UJDQL]DWLRQ$YHQXH$SSLD 1211 Geneva 27, Switzerland WHOID[HPDLOERRNRUGHUV#ZKRLQW Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/ FRS\ULJKWBIRUPLQGH[KWPO The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. 7KHPHQWLRQRIVSHFLnjFFRPSDQLHVRURIFHUWDLQPDQXIDFWXUHUVšSURGXFWV does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Printed by the WHO Document Production Services, Geneva, Switzerland WHO GUIDELINES FOR THE TREATMENT OF CHLAMYDIA TRACHOMATIS i CONTENTS Acknowledgements iii Abbreviations and acronyms iv Executive summary 1 Overview of the guidelines for the prevention, treatment and management of STIs 6 67,HSLGHPLRORJ\DQGEXUGHQ :K\QHZJXLGHOLQHVIRUWKHSUHYHQWLRQWUHDWPHQWDQGPDQDJHPHQWRI67,V" Approach to the revision of STI guidelines 8 References 9 WHO guidelines for the treatment of Chlamydia trachomatis 10 1. Introduction 10 (SLGHPLRORJ\EXUGHQDQGFOLQLFDOFRQVLGHUDWLRQV &OLQLFDOSUHVHQWDWLRQ Laboratory diagnosis 11 1.2 Rationale for new recommendations 11 1.3 Objectives 11 1.4 Target audience 11 1.5 Structure of the guidelines 11 2. Methods 12 *XLGHOLQH'HYHORSPHQW*URXS *'* 2.2 Questions and outcomes 12 2.3 Reviews of the evidence 12 2.4 Making recommendations 13 0DQDJHPHQWRIFRQǍLFWVRILQWHUHVW 3. Dissemination, updating and implementation of the guidelines 15 3.1 Dissemination 15 3.2 Updating the STI guidelines and user feedback 15 3.3 Implementation of the WHO guidelines for the treatment of C. trachomatis 15 Adaptation, implementation and monitoring 15 ,GHQWLI\LQJDQGSURFXULQJ67,GUXJV 4. Recommendations for treatment of chlamydial infections 17 4.1 Uncomplicated genital chlamydia 17 Recommendation 1 17 4.2 Anorectal chlamydial infection 18 Recommendation 2 18 4.3 Chlamydial infection in pregnant women 19 Recommendation 3a 19 Recommendation 3b 19 Recommendation 3c 19 /\PSKRJUDQXORPDYHQHUHXP /*9 5HFRPPHQGDWLRQ ii WHO GUIDELINES FOR THE TREATMENT OF CHLAMYDIA TRACHOMATIS &217(176 &217,18(' 2SKWKDOPLDQHRQDWRUXP 5HFRPPHQGDWLRQ 5HFRPPHQGDWLRQ Recommendation 7 21 References 22 Annex A: STI guideline development teams 23 Annex B: Detailed methods for guideline development 32 Questions and outcomes 32 Review of the evidence 35 Applying the GRADE approach to making the recommendations 38 Annex C: Lists of references for reviewed evidence 39 Recommendation 1 39 5HFRPPHQGDWLRQ Recommendation 3a, 3b, 3c 41 Recommendation 4 42 Recommendation 5 43 5HFRPPHQGDWLRQVDQG Web annexes available at: www.who.int/reproductivehealth/publications/rtis/chlamydia-treatment-guidelines/en/ :HEDQQH['(YLGHQFHSURnjOHVDQGHYLGHQFHWRGHFLVLRQIUDPHZRUNV Web annex E: Systematic reviews for chlamydia guidelines :HEDQQH[)6XPPDU\RIFRQǍLFWVRILQWHUHVW WHO GUIDELINES FOR THE TREATMENT OF CHLAMYDIA TRACHOMATIS iii ACKNOWLEDGEMENTS The Department of Reproductive Health and Research Members: <DZ 6D[ $GX6DUNRGLH$QGUHZ$PDWR DWWKH:RUOG+HDOWK2UJDQL]DWLRQ :+2 ZRXOGOLNHWR Gail Bolan, John Changalucha, Xiang-Sheng Chen, thank the members of the STI Guideline Development Harrel Chesson, Craig Cohen, Francisco Garcia, Group for their consistent availability and commitment Suzanne Garland, Sarah Hawkes, Mary Higgins, to making these guidelines possible. The Department .LQJ+ROPHV-HNjUH\.ODXVQHU'DYLG/HZLV1LFROD/RZ is also grateful to the STI External Review Group for David Mabey, Angelica Espinosa Miranda, Nelly Mugo, peer reviewing these guidelines, and appreciates Saiqa Mullick, Francis Ndowa, Joel Palefsky, the contribution of the WHO Steering Committee. .HLWK5DGFOLNjH8OXJEHN6DELURY-XGLWK6WHSKHQVRQ The names of the members of each group are listed Richard Steen, Magnus Unemo, Bea Vuylsteke, below, with full details provided in Annex A. Anna Wald, Thomas Wong and Kimberly A. Workowski Special thanks to Dr Nancy Santesso, the guideline STI GDG working group for chlamydia: methodologist who also led the systematic review Andrew Amato, Harrell Chesson, Craig Cohen, SURFHVVIRUKHUKDUGZRUNDQGnjUPFRPPLWPHQWRI Patricia Garcia, Nicola Low, David Mabey, Angelica the guideline development process. We also thank 0LUDQGD)UDQFLV1GRZD.HLWK5DGFOLNjH-XGLWK the members of the Systematic Review Team from Stephenson, Magnus Unemo, Bea Vuylsteke and McMaster University. Judith Wasserheit We appreciate the overall support of the WHO STI External Review Group: Laith Abu-Raddad, Guideline Review Committee Secretariat during the Adele Benaken-Schwartz, Mircea Betiu, Anupong guideline development process, with grateful thanks Chitwarakorn, Anjana Das, Carolyn Deal, to Dr Susan Norris. Margaret Gale-Rowe, William M. Geisler, Amina El Kettani, Mizan Kiros, Ahmed Latif, Philippe We thank Theresa Ryle for the administrative Mayaud, David McCartney, Ali M. Mir, Nuriye Ortayli, VXSSRUWDQG&RPPXQLFDWLRQVIRUDVVLVWDQFH Khantanouvieng Sayabounthavong and with the guideline design and layout. This guideline Aman Kumar Singh document was edited by Ms Jane Patten, of Green Ink, United Kingdom. WHO Steering Committee: Dr Teodora Wi led the guideline development process :+2UHJLRQDORǎFHVMassimo Ghidinelli, Hamida and Dr Nathalie Broutet co-led the process under Khattabi, Lali Khotenashvili, Ornella Lincetto Ying-Ru Lo, the supervision of Dr James Kiarie and leadership of Frank Lule and Razia Pendse Dr Ian Askew. Lee Sharkey provided support during WHO headquarters: Moazzam Ali, Avni Amin, Rachel the guideline development process. Baggaley, Venkatraman Chandra-Mouli, Jane Ferguson, 0DULR)HVWLQ0DU\/\Q*DǎHOG$QWRQLR*HUEDVH FUNDING Sami Gottlieb, Silvio Paolo Mariotti, Frances McConville, Lori Newman, Annette Mwansa Nkowane, Anita Sands, The preparation and printing of the guidelines were Igor Toskin and Marco Vitoria funded exclusively by the UNDP/UNFPA/UNICEF/ WHO/World Bank Special Programme of Research, WHO STI Secretariat: Ian Askew, Teodora Elvira Wi Development and Research Training in Human OHDGGHYHORSPHQWRIWKHJXLGHOLQHV 1DWKDOLH%URXWHW 5HSURGXFWLRQ +53 1RH[WHUQDOVRXUFHRIIXQGLQJ FROHDGGHYHORSPHQWRIWKHJXLGHOLQHV -DPHV.LDULH was solicited or utilized. and Lee Sharkey Systematic Review Team: 1DQF\6DQWHVVR OHDG CONTRIBUTORS TO WHO GUIDELINES FOR THE Housne Begum, Janna-Lina Kerth, Gian Paolo Morgano, TREATMENT OF CHLAMYDIA TRACHOMATIS Kristie Poole, Nicole Schwab, Matthew Ventresca, <XDQ=KDQJDQG$QGUHZ=LNLF PHPEHUV STI Guideline Development Group (GDG): Methodologist: Nancy Santesso. Chairpersons: Judith Wasserheit, Holger Schünemann and Patricia Garcia iv WHO GUIDELINES FOR THE TREATMENT OF CHLAMYDIA TRACHOMATIS ABBREVIATIONS AND ACRONYMS AIDS DFTXLUHGLPPXQHGHnjFLHQF\V\QGURPH AMR antimicrobial resistance DALY disability-adjusted life year DFA GLUHFWǍXRUHVFHQWDQWLERG\ DOI declaration of interests ELISA enzyme-linked immunosorbent assays GDG Guideline Development Group GRADE Grading of Recommendations Assessment, Development and Evaluation GUD genital ulcer disease HIV KXPDQLPPXQRGHnjFLHQF\YLUXV HPV human papillomavirus HRP UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction +69 herpes simplex virus type 2 LGV lymphogranuloma venereum MSH Management Sciences for Health MSM men who have sex with men NAATs QXFOHLFDFLGDPSOLnjFDWLRQWHVWV 1$$7V PICO population, intervention, comparator, outcome POCT point-of-care test STI sexually transmitted infection UNAIDS Joint United Nations Programme on HIV/AIDS UNFPA United Nations Population Fund UNICEF 8QLWHG1DWLRQV&KLOGUHQšV)XQG WHO World Health Organization WHO GUIDELINES FOR THE TREATMENT OF CHLAMYDIA TRACHOMATIS 1 WHO GUIDELINES FOR THE TREATMENT OF CHLAMYDIA TRACHOMATIS EXECUTIVE SUMMARY Sexually transmitted infections (STIs) are a PDMRUSXEOLFKHDOWKSUREOHPZRUOGZLGHDNjHFWLQJ TXDOLW\RIOLIHDQGFDXVLQJVHULRXVPRUELGLW\ and mortality. STIs have a direct impact on UHSURGXFWLYHDQGFKLOGKHDOWKWKURXJKLQIHUWLOLW\
Load more

Recommended publications
  • Infectious Disease
    INFECTIOUS DISEASE Infectious diseases are caused by germs that are transmitted directly from person to NOTE: person; animal to person (zoonotic The following symbols are used throughout this Community Health Assessment Report to serve only as a simple and quick diseases); from mother to unborn child; or reference for data comparisons and trends for the County. indirectly, such as when a person touches Further analysis may be required before drawing conclusions about the data. a surface that some germs can linger on. The NYSDOH recommends several The apple symbol represents areas in which Oneida County’s status or trend is FAVORABLE or COMPARABLE to its effective strategies for preventing comparison (i.e., NYS, US) or areas/issues identified as infectious diseases,, including: ensuring STRENGTHS. procedures and systems are in place in The magnifying glass symbols represent areas in which Oneida County’s status or trend is UNFAVORABLE to its communities for immunizations to be up to comparison (i.e., NYS, US) or areas/issues of CONCERN date; enabling sanitary practices by or NEED that may warrant further analysis. conveniently located sinks for washing DATA REFERENCES: hands; influencing community resources • All References to tables are in Attachment A – Oneida County Data Book. and cultures to facilitate abstinence and • See also Attachment B – Oneida County Chart Book for risk reduction practices for sexual behavior additional data. and injection drug use, and setting up support systems to ensure medicines are taken as prescribed.453 The reporting of suspect or confirmed communicable diseases is mandated under the New York State Sanitary Code (10NYCRR 2.10).
    [Show full text]
  • Chlamydia-English
    URGENT and PRIVATE IMPORTANT INFORMATION ABOUT YOUR HEALTH DIRECTIONS FOR SEX PARTNERS OF PERSONS WITH CHLAMYDIA PLEASE READ THIS VERY CAREFULLY Your sex partner has recently been treated for chlamydia. Chlamydia is a sexually transmitted disease (STD) that you can get from having any kind of sex (oral, vaginal, or anal) with a person who already has it. You may have been exposed. The good news is that it’s easily treated. You are being given a medicine called azithromycin (sometimes known as “Zithromax”) to treat your chlamydia. Your partner may have given you the actual medicine, or a prescription that you can take to a pharmacy. These are instructions for how to take azithromycin. The best way to take care of this infection is to see your own doctor or clinic provider right away. If you can’t get to a doctor in the next several days, you should take the azithromycin. Even if you decide to take the medicine, it is very important to see a doctor as soon as you can, to get tested for other STDs. People can have more than one STD at the same time. Azithromycin will not cure other sexually transmitted infections. Having STDs can increase your risk of getting HIV, so make sure to also get an HIV test. SYMPTOMS Some people with chlamydia have symptoms, but most do not. Symptoms may include pain in your testicles, pelvis, or lower part of your belly. You may also have pain when you urinate or when having sex. Many people with chlamydia do not know they are infected because they feel fine.
    [Show full text]
  • Compendium of Measures to Control Chlamydia Psittaci Infection Among
    Compendium of Measures to Control Chlamydia psittaci Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2017 Author(s): Gary Balsamo, DVM, MPH&TMCo-chair Angela M. Maxted, DVM, MS, PhD, Dipl ACVPM Joanne W. Midla, VMD, MPH, Dipl ACVPM Julia M. Murphy, DVM, MS, Dipl ACVPMCo-chair Ron Wohrle, DVM Thomas M. Edling, DVM, MSpVM, MPH (Pet Industry Joint Advisory Council) Pilar H. Fish, DVM (American Association of Zoo Veterinarians) Keven Flammer, DVM, Dipl ABVP (Avian) (Association of Avian Veterinarians) Denise Hyde, PharmD, RP Preeta K. Kutty, MD, MPH Miwako Kobayashi, MD, MPH Bettina Helm, DVM, MPH Brit Oiulfstad, DVM, MPH (Council of State and Territorial Epidemiologists) Branson W. Ritchie, DVM, MS, PhD, Dipl ABVP, Dipl ECZM (Avian) Mary Grace Stobierski, DVM, MPH, Dipl ACVPM (American Veterinary Medical Association Council on Public Health and Regulatory Veterinary Medicine) Karen Ehnert, and DVM, MPVM, Dipl ACVPM (American Veterinary Medical Association Council on Public Health and Regulatory Veterinary Medicine) Thomas N. Tully JrDVM, MS, Dipl ABVP (Avian), Dipl ECZM (Avian) (Association of Avian Veterinarians) Source: Journal of Avian Medicine and Surgery, 31(3):262-282. Published By: Association of Avian Veterinarians https://doi.org/10.1647/217-265 URL: http://www.bioone.org/doi/full/10.1647/217-265 BioOne (www.bioone.org) is a nonprofit, online aggregation of core research in the biological, ecological, and environmental sciences. BioOne provides a sustainable online platform for over 170 journals and books published by nonprofit societies, associations, museums, institutions, and presses. Your use of this PDF, the BioOne Web site, and all posted and associated content indicates your acceptance of BioOne’s Terms of Use, available at www.bioone.org/page/terms_of_use.
    [Show full text]
  • Pdf/Bookshelf NBK368467.Pdf
    BMJ 2019;365:l4159 doi: 10.1136/bmj.l4159 (Published 28 June 2019) Page 1 of 11 Practice BMJ: first published as 10.1136/bmj.l4159 on 28 June 2019. Downloaded from PRACTICE CLINICAL UPDATES Syphilis OPEN ACCESS Patrick O'Byrne associate professor, nurse practitioner 1 2, Paul MacPherson infectious disease specialist 3 1School of Nursing, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada; 2Sexual Health Clinic, Ottawa Public Health, Ottawa, Ontario K1N 5P9; 3Division of Infectious Diseases, Ottawa Hospital General Campus, Ottawa, Ontario What you need to know Box 1: Symptoms of syphilis by stage of infection (see fig 1) • Incidence rates of syphilis have increased substantially around the Primary world, mostly affecting men who have sex with men and people infected • Symptoms appear 10-90 days (mean 21 days) after exposure with HIV http://www.bmj.com/ • Main symptom is a <2 cm chancre: • Have a high index of suspicion for syphilis in any sexually active patient – Progresses from a macule to papule to ulcer over 7 days with genital lesions or rashes – Painless, solitary, indurated, clean base (98% specific, 31% sensitive) • Primary syphilis classically presents as a single, painless, indurated genital ulcer (chancre), but this presentation is only 31% sensitive; – On glans, corona, labia, fourchette, or perineum lesions can be painful, multiple, and extra-genital – A third are extragenital in men who have sex with men and in women • Diagnosis is usually based on serology, using a combination of treponemal and non-treponemal tests. Syphilis remains sensitive to • Localised painless adenopathy benzathine penicillin G Secondary on 24 September 2021 by guest.
    [Show full text]
  • 2020 European Guideline on the Management of Syphilis
    DOI: 10.1111/jdv.16946 JEADV GUIDELINES 2020 European guideline on the management of syphilis M. Janier,1,* M. Unemo,2 N. Dupin,3 G.S. Tiplica,4 M. Potocnik, 5 R. Patel6 1STD Clinic, Hopital^ Saint-Louis AP-HP and Hopital^ Saint-Joseph, Paris, France 2WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Department of Laboratory Medicine, Microbiology, Orebro€ University Hospital and Orebro€ University, Orebro,€ Sweden 3Syphilis National Reference Center, Hopital^ Tarnier-Cochin, AP-HP, Paris, France 42nd Dermatological Clinic, Carol Davila University, Colentina Clinical Hospital, Bucharest, Romania 5Department of Dermatovenereology, University Medical Centre Ljubljana, Ljubljana, Slovenia 6Department of Genitourinary Medicine, the Royal South Hants Hospital, Southampton, UK *Correspondence to: M. Janier. E-mail: [email protected] Abstract The 2020 edition of the European guideline on the management of syphilis is an update of the 2014 edition. Main modifications and updates include: - The ongoing epidemics of early syphilis in Europe, particularly in men who have sex with men (MSM) - The development of dual treponemal and non-treponemal point-of-care (POC) tests - The progress in non-treponemal test (NTT) automatization - The regular episodic shortage of benzathine penicillin G (BPG) in some European countries - The exclusion of azithromycin as an alternative treatment at any stage of syphilis - The pre-exposure or immediate post-exposure prophylaxis with doxycycline in populations at high risk of acquiring syphilis. Received: 12 June 2020; Accepted: 4 September 2020 Conflicts of interest The authors have no conflicts of interest related to this guideline. Funding sources None. Introduction EEA countries and particularly among men who have sex with Syphilis is a systemic human disease due to Treponema pallidum men (MSM).3 subsp.
    [Show full text]
  • Reportable Disease Surveillance in Virginia, 2013
    Reportable Disease Surveillance in Virginia, 2013 Marissa J. Levine, MD, MPH State Health Commissioner Report Production Team: Division of Surveillance and Investigation, Division of Disease Prevention, Division of Environmental Epidemiology, and Division of Immunization Virginia Department of Health Post Office Box 2448 Richmond, Virginia 23218 www.vdh.virginia.gov ACKNOWLEDGEMENT In addition to the employees of the work units listed below, the Office of Epidemiology would like to acknowledge the contributions of all those engaged in disease surveillance and control activities across the state throughout the year. We appreciate the commitment to public health of all epidemiology staff in local and district health departments and the Regional and Central Offices, as well as the conscientious work of nurses, environmental health specialists, infection preventionists, physicians, laboratory staff, and administrators. These persons report or manage disease surveillance data on an ongoing basis and diligently strive to control morbidity in Virginia. This report would not be possible without the efforts of all those who collect and follow up on morbidity reports. Divisions in the Virginia Department of Health Office of Epidemiology Disease Prevention Telephone: 804-864-7964 Environmental Epidemiology Telephone: 804-864-8182 Immunization Telephone: 804-864-8055 Surveillance and Investigation Telephone: 804-864-8141 TABLE OF CONTENTS INTRODUCTION Introduction ......................................................................................................................................1
    [Show full text]
  • WHO GUIDELINES for the Treatment of Treponema Pallidum (Syphilis)
    WHO GUIDELINES FOR THE Treatment of Treponema pallidum (syphilis) WHO GUIDELINES FOR THE Treatment of Treponema pallidum (syphilis) WHO Library Cataloguing-in-Publication Data WHO guidelines for the treatment of Treponema pallidum (syphilis). Contents: Web annex D: Evidence profiles and evidence-to-decision frameworks - Web annex E: Systematic reviews for syphilis guidelines - Web annex F: Summary of conflicts of interest 1.Syphilis – drug therapy. 2.Treponema pallidum. 3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154980 6 (NLM classification: WC 170) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/ copyright_form/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Genital Herpes and Human Immunodeficiency Virus
    Genital herpes and human immunodeficiency virus: double trouble Connie Celum,1 Ruth Levine,2 Marcia Weaver,3 & Anna Wald1 Abstract The synergistic relationship between herpes simplex virus type 2 (HSV-2) and transmission of human immunodeficiency virus (HIV) can be substantial in developing countries that have high prevalences of both viral infections. Genital herpes, most frequently caused by HSV-2, has become the leading cause of genital ulcer disease worldwide. This review of recent research on genital herpes and enhanced susceptibility to, and transmission of, HIV is part of the “Advances in HIV/AIDS research series” which endeavours to form a bridge between the research into HIV and acquired immunodeficiency syndrome (AIDS) and the practice of HIV/AIDS prevention, care and support in developing countries. Research findings have shown that being seropositive for HSV-2 can increase the risk of HIV acquisition among high-risk HIV-negative people exposed to HIV and, likewise, the infectiousness of individuals co-infected with HIV-1 and HSV-2 can increase during periods of HSV-2 reactivation. These observations have led to the initiation of several intervention trials and could ultimately lead to the setting of new priorities in public health and clinical practice. WHO has recently issued new guidelines for the syndromic management of genital ulcer disease that include antiviral treatment for lesions consistent with genital herpes. The United States Centers for Disease Control and Prevention issued updated Sexually Transmitted Diseases Treatment Guidelines in 2002 that recommended the use of type-specific serological tests for diagnosing HSV-2. Recently launched proof-of-concept, HSV-2 intervention trials in several countries will help to determine the proportion of new HIV infections that could be prevented by suppression of HSV-2, and the findings from these studies will inform those involved in setting prevention and treatment priorities and strategies in developing countries.
    [Show full text]
  • Chlamydia Trachomatis Infection Is Driven by Nonprotective Immune Cells That Are Distinct from Protective Populations
    Pathology after Chlamydia trachomatis infection is driven by nonprotective immune cells that are distinct from protective populations Rebeccah S. Lijeka,b,1, Jennifer D. Helblea, Andrew J. Olivea,c, Kyra W. Seigerb, and Michael N. Starnbacha,1 aDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115; bDepartment of Biological Sciences, Mount Holyoke College, South Hadley, MA 01075; and cDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01605 Edited by Rafi Ahmed, Emory University, Atlanta, GA, and approved December 27, 2017 (received for review June 23, 2017) Infection with Chlamydia trachomatis drives severe mucosal immu- sequence identity, Chlamydia muridarum, the extent to which the nopathology; however, the immune responses that are required for molecular pathogenesis of C. muridarum represents that of Ct is mediating pathology vs. protection are not well understood. Here, unknown (6). Ct serovar L2 (Ct L2) is capable of infecting the we employed a mouse model to identify immune responses re- mouse upper genital tract when inoculated across the cervix into quired for C. trachomatis-induced upper genital tract pathology the uterus (7, 8) but it does not induce robust immunopathology. and to determine whether these responses are also required for This is consistent with the human disease phenotype caused by Ct L2, bacterial clearance. In mice as in humans, immunopathology was which disseminates to the lymph nodes causing lymphogranuloma characterized by extravasation of leukocytes into the upper genital venereum (LGV) and is not a major cause of mucosal immunopa- thology in the female upper genital tract (uterus and ovaries). tract that occluded luminal spaces in the uterus and ovaries.
    [Show full text]
  • Leptospirosis: a Waterborne Zoonotic Disease of Global Importance
    August 2006 volume 22 number 08 Leptospirosis: A waterborne zoonotic disease of global importance INTRODUCTION syndrome has two phases: a septicemic and an immune phase (Levett, 2005). Leptospirosis is considered one of the most common zoonotic diseases It is in the immune phase that organ-specific damage and more severe illness globally. In the United States, outbreaks are increasingly being reported is seen. See text box for more information on the two phases. The typical among those participating in recreational water activities (Centers for Disease presenting signs of leptospirosis in humans are fever, headache, chills, con- Control and Prevention [CDC], 1996, 1998, and 2001) and sporadic cases are junctival suffusion, and myalgia (particularly in calf and lumbar areas) often underdiagnosed. With the onset of warm temperatures, increased (Heymann, 2004). Less common signs include a biphasic fever, meningitis, outdoor activities, and travel, Georgia may expect to see more leptospirosis photosensitivity, rash, and hepatic or renal failure. cases. DIAGNOSIS OF LEPTOSPIROSIS Leptospirosis is a zoonosis caused by infection with the bacterium Leptospira Detecting serum antibodies against leptospira interrogans. The disease occurs worldwide, but it is most common in temper- • Microscopic Agglutination Titers (MAT) ate regions in the late summer and early fall and in tropical regions during o Paired serum samples which show a four-fold rise in rainy seasons. It is not surprising that Hawaii has the highest incidence of titer confirm the diagnosis; a single high titer in a per- leptospirosis in the United States (Levett, 2005). The reservoir of pathogenic son clinically suspected to have leptospirosis is highly leptospires is the renal tubules of wild and domestic animals.
    [Show full text]
  • Gonorrhea, Chlamydia, and Syphilis
    2019 GONORRHEA, CHLAMYDIA, AND SYPHILIS AND CHLAMYDIA, GONORRHEA, Dedication TAG would like to thank the National Coalition of STD Directors for funding and input on the report. THE PIPELINE REPORT Pipeline for Gonorrhea, Chlamydia, and Syphilis By Jeremiah Johnson Introduction The current toolbox for addressing gonorrhea, chlamydia, and syphilis is inadequate. At a time where all three epidemics are dramatically expanding in locations all around the globe, including record-breaking rates of new infections in the United States, stakeholders must make do with old tools, inadequate systems for addressing sexual health, and a sparse research pipeline of new treatment, prevention, and diagnostic options. Lack of investment in sexual health research has left the field with inadequate prevention options, and limited access to infrastructure for testing and treatment have allowed sexually transmitted infections (STIs) to flourish. The consequences of this underinvestment are large: according to the World Health Organization (WHO), in 2012 there were an estimated 357 million new infections (roughly 1 million per day) of the four curable STIs: gonorrhea, chlamydia, syphilis, and trichomoniasis.1 In the United States, the three reportable STIs that are the focus of this report—gonorrhea, chlamydia, and syphilis—are growing at record paces. In 2017, a total of 30,644 cases of primary and secondary (P&S) syphilis—the most infectious stages of the disease—were reported in the United States. Since reaching a historic low in 2000 and 2001, the rate of P&S syphilis has increased almost every year, increasing 10.5% during 2016–2017. Also in 2017, 555,608 cases of gonorrhea were reported to the U.S.
    [Show full text]
  • STD Glossary of Terms
    STD 101 In A Box- STD Glossary of Terms Abstinence Not having sexual intercourse Acquired A disease of the human immune system caused by the Human Immunodeficiency Virus (HIV). HIV/AIDS represents the entire range of Immunodeficiency disease caused by the HIV virus from early infection to late stage Syndrome (AIDS) symptoms. Anal Intercourse Sexual contact in which the penis enters the anus. Antibiotic A medication that either kills or inhibits the growth of a bacteria. Antiviral A medication that either kills or inhibits the growth of a virus. A thinning of tissue modified by the location. In epidermal atrophy, the epidermis becomes transparent with a loss of skin texture and cigarette Atrophic paper-like wrinkling. In dermal atrophy, there is a loss of connective tissue and the lesion is depressed. A polymicrobial clinical syndrome resulting from replacement of the Bacterial Vaginosis normal hydrogen peroxide producing Lactobacillus sp. in the vagina with (BV) high concentrations of anaerobic bacteria. The common symptom of BV is abnormal homogeneous, off-white, fishy smelling vaginal discharge. Cervical Motion A sign found on pelvic examination suggestive of pelvic pathology; when Tenderness (CMT) movement of the cervix during the bimanual exam elicits pain. The lower, cylindrical end of the uterus that forms a narrow canal Cervix connecting the upper (uterus) and lower (vagina) parts of a woman's reproductive tract. The most common sexually transmitted bacterial infection in the U.S., caused by the bacteria Chlamydia trachomatis. Often no symptoms are present, especially in women. Untreated chlamydia can cause sterility, Chlamydia Pelvic Inflammatory Disease (PID), and increase the chances for life- threatening tubal pregnancies.
    [Show full text]